Typing of ovarian carcinomas: An update

Diagnostic Histopathology

Volumn 17, Issue 4, 2011, Pages 165-177

  Przybycin, Christopher G ^a   Soslow, Robert A ^b  

^a Clin Path Associates   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clear cell; Endometrioid; Mucinous; Ovarian carcinoma; Serous

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROTEIN P53;

ARTICLE; CANCER CLASSIFICATION; CLEAR CELL CARCINOMA; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; MIXED EPITHELIAL OVARIAN TUMOR; MUCINOUS CARCINOMA; OVARY CARCINOMA; OVARY SEROUS CARCINOMA; PREVALENCE; TRANSITIONAL CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA;

EID: 79952897535     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2011.01.005     Document Type: Article

References (88)

1. Kobel M., Kalloger S.E., Huntsman D.G., et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol May 2010, 29:203-211.
2. Singer G., Kurman R.J., Chang H.W., Cho S.K.R., Shih I.M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002, 160:1223-1228.
3. Singer G., Stohr R., Cope L., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005, 29:218-224.
4. Gilks C.B., Ionescu D.N., Kalloger S.E., et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol Aug 2008, 39:1239-1251.
5. Kobel M., Kalloger S.E., Santos J.L., Huntsman D.G., Gilks C.B., Swenerton K.D. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol Jan 2010, 116:50-56.
6. Gershenson D.M., Sun C.C., Lu K.H., et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol Aug 2006, 108:361-368.
7. Sugiyama T., Kamura T., Kigawa J., et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer Jun 1, 2000, 88:2584-2589.
8. Itamochi H., Kigawa J., Sugiyama T., Kikuchi Y., Suzuki M., Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002, 100:281-287.
9. Pectasides D., Fountzilas G., Aravantinos G., et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006, 102:285-291.
10. Eltabbakh G.H., Mount S.L., Beatty B., Simmons-Arnold L., Cooper K. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol Apr 1, 2006, 93:379-386.
11. Swenerton K.D., Santos J.L., Gilks C.B., et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol Feb 2011, 22:341-347.
12. Kobel M., Kalloger S.E., Baker P.M., et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol Jul 2010, 34:984-993.
13. Seidman J.D., Horkayne-Szakaly I., Cosin J.A., et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006, 103:703-708.
14. Kurman R.J., Shih Ie.M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol Mar 2010, 34:433-443.
15. Carlson J., Roh M.H., Chang M.C., Crum C.P. Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube. Diagn Histopathol Aug 2008, 14:352-365.
16. Przybycin C.G., Kurman R.J., Ronnett B.M., Shih Ie.M., Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am J Surg Pathol Oct 2010, 34:1407-1416.
17. Malpica A., Deavers M.T., Lu K., et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004, 28:496-504.
18. Malpica A., Deavers M.T., Tornos C., et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 2007, 31:1168-1174.
19. Clarke B., Tinker A.V., Lee C.H., et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol Mar 2009, 22:393-402.
20. Kupryjanczyk J., Thor A.D., Beauchamp R., et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993, 90:4961-4965.
21. Teneriello M.G., Ebina M., Linnoila R.I., et al. p53 And Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993, 53:3103-3108.
22. Leitao M.M., Soslow R.A., Baergen R.N., Olvera N., Arroyo C., Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004, 93:301-306.
23. Kobel M., Reuss A., Bois A., et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol Oct 2010, 222:191-198.
24. Han G., Gilks C.B., Leung S., et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol Jul 2008, 32:955-964.
25. Eichhorn J.H., Young R.H. Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol 2004, 28:453-463.
26. Bell D.A., Longacre T.A., Prat J., et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol Aug 2004, 35:934-948.
27. Singer G., Oldt R., Cohen Y., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95:484-486.
28. Singer G., Shih I., Truskinovsky A., Umudum H., Kurman R.J. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol 2003, 22:37-41.
29. Alvarez A.A., Moore W.F., Robboy S.J., et al. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Gynecol Oncol Feb 2001, 80:201-206.
30. Mayr D., Hirschmann A., Lohrs U., Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006, 103:883-887.
31. Burks R.T., Sherman M.E., Kurman R.J. Micropapillary serous carcinoma of the ovary - a distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol Nov 1996, 20:1319-1330.
32. Ayhan A., Kurman R.J., Yemelyanova A., et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol Aug 2009, 33:1220-1224.
33. Evans-Metcalf E.R., Brooks S.E., Reale F.R., Baker S.P. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998, 91:349-354.
34. Gitsch G., Hanzal E., Jensen D., Hacker N.F. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995, 85:504-508.
35. Garg K., Shih K., Barakat R., Zhou Q., Iasonos A., Soslow R.A. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol Dec 2009, 33:1869-1877.
36. Shimizu Y., Kamoi S., Amada S., Akiyama F., Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma - testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998, 82:893-901.
37. Shimizu Y., Kamoi S., Amada S., Hasumi K., Akiyama F., Silverberg S.G. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system [see comments]. Gynecol Oncol 1998, 70:2-12.
38. Catasus L., Bussaglia E., Rodrguez I., et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004, 35:1360-1368.
39. Irving J.A., Catasus L., Gallardo A., et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 2005, 36:605-619.
40. Wu R., Hendrix-Lucas N., Kuick R., et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell Apr 2007, 11:321-333.
41. Willner J., Wurz K., Allison K.H., et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol 2007, 38:607-613.
42. Sato N., Tsunoda H., Nishida M., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
43. Moreno-Bueno G., Gamallo C., Perez-Gallego L., De Mora J.C., Suarez A., Palacios J. Beta-catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001, 10:116-122.
44. Silva E.G., Young R.H. Endometrioid neoplasms with clear cells: a report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol 2007, 31:1203-1208.
45. Roth L.M., Emerson R.E., Ulbright T.M. Ovarian endometrioid tumors of low malignant potential: a clinicopathologic study of 30 cases with comparison to well-differentiated endometrioid adenocarcinoma. Am J Surg Pathol 2003, 27:1253-1259.
46. Bell K.A., Kurman R.J. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 2000, 24:1465-1479.
47. Chen S., Leitao M.M., Tornos C., Soslow R.A. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 2005, 18:903-911.
48. Roth L.M., Liban E., Czernobilsky B. Ovarian endometrioid tumors mimicking Sertoli and Sertoli-Leydig cell tumors: Sertoliform variant of endometrioid carcinoma. Cancer 1982, 50:1322-1331.
49. Ordi J., Schammel D.P., Rasekh L., Tavassoli F.A. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 1999, 12:933-940.
50. Oliva E., Alvarez T., Young R.H. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol 2005, 29:143-156.
51. Tornos C., Silva E.G., Ordonez N.G., Gershenson D.M., Young R.H., Scully R.E. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion - a report of 14 cases. Am J Surg Pathol 1995, 19:1343-1353.
52. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004, 23:41-44.
53. Leitao M.M., Boyd J., Hummer A., et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 2004, 28:147-159.
54. DeLair D., Soslow R., Gilks B., Macias A., Oliva E. The morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 83 cases. Mod Pathol 2009, 22(suppl 1):211A. (abstract 961).
55. Yamamoto S., Tsuda H., Yoshikawa T., et al. Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol 2007, 31:999-1006.
56. Veras E., Mao T.L., Ayhan A., et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol Jun 2009, 33:844-853.
57. Kobel M., Kalloger S.E., Carrick J., et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol Jan 2009, 33:14-21.
58. Shimizu M., Nikaido T., Toki T., Shiozawa T., Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer 1999, 85:669-677.
59. Tsuchiya A., Sakamoto M., Yasuda J., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol Dec 2003, 163:2503-2512.
60. Kuo K.T., Mao T.L., Jones S., et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol May 2009, 174:1597-1601.
61. Gras E., Catasus L., Argueelles R., et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 2001, 92:2829-2836.
62. Ueda H., Watanabe Y., Nakai H., Hemmi H., Koi M., Hoshiai H. Microsatellite status and immunohistochemical features of ovarian clear-cell carcinoma. Anticancer Res Jul-Aug 2005, 25:2785-2788.
63. Wiegand K.C., Shah S.P., Al-Agha O.M., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med Oct 14, 2010, 363:1532-1543.
64. Cao D., Guo S., Allan R.W., Molberg K.H., Peng Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol Jun 2009, 33:894-904.
65. Seidman J.D., Kurman R.J., Ronnett B.M. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003, 27:985-993.
66. Yemelyanova A.V., Vang R., Judson K., Wu L.S., Ronnett B.M. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol Jan 2008, 32:128-138.
67. Khunamornpong S., Siriaunkgul S., Suprasert P., Pojchamarnwiputh S., Na C.W., Young R.H. Intrahepatic cholangiocarcinoma metastatic to the ovary: a report of 16 cases of an underemphasized form of secondary tumor in the ovary that may mimic primary neoplasia. Am J Surg Pathol 2007, 31:1788-1799.
68. Khunamornpong S., Suprasert P., Chiangmai W.N., Siriaunkgul S. Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. Int J Gynecol Cancer 2006, 16(suppl 1):132-138.
69. Riopel M.A., Ronnett B.M., Kurman R.J. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999, 23:617-635.
70. Lee K.R., Scully R.E. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000, 24:1447-1464.
71. Rodriguez I.M., Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002, 26:139-152.
72. Vang R., Gown A.M., Barry T.S., et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006, 30:1130-1139.
73. Ji H., Isacson C., Seidman J.D., Kurman R.J., Ronnett B.M. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002, 21:391-400.
74. Ronnett B.M., Kurman R.J., Shmookler B.M., Sugarbaker P.H., Young R.H. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas - a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997, 21:1144-1155.
75. Ronnett B.M., Shmookler B.M., Diener-West M., Sugarbaker P.H., Kurman R.J. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997, 16:1-9.
76. Elishaev E., Gilks C.B., Miller D., Srodon M., Kurman R.J., Ronnett B.M. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol 2005, 29:281-294.
77. Gemignani M.L., Schlaerth A.C., Bogomolniy F., et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003, 90:378-381.
78. Enomoto T., Weghorst C.M., Inoue M., Tanizawa O., Rice J.M. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol Oct 1991, 139:777-785.
79. McAlpine J.N., Wiegand K.C., Vang R., et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009, 9:433.
80. McKenney J.K., Soslow R.A., Longacre T.A. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol 2008, 32:645-655.
81. Vang R., Gown A.M., Zhao C., et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol 2007, 31:854-869.
82. Ronnett B.M., Seidman J.D. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 2003, 27:650-657.
83. Logani S., Oliva E., Amin M.B., Folpe A.L., Cohen C., Young R.H. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 2003, 27:1434-1441.
84. Kommoss F., Kommoss S., Schmidt D., Trunk M.J., Pfisterer J., Du B.A. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 2005, 97:195-199.
85. Robey S.S., Silva E.G., Gershenson D.M., McLemore D., el-Naggar A., Ordonez N.G. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 1989, 63:839-847.
86. Silva E.G., Robey-Cafferty S.S., Smith T.L., Gershenson D.M. Ovarian carcinomas with transitional cell carcinoma pattern. Am J Clin Pathol 1990, 93:457-465.
87. Altrabulsi B., Malpica A., Deavers M.T., Bodurka D.C., Broaddus R., Silva E.G. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005, 29:1316-1321.
88. Tafe L.J., Garg K., Chew I., Tornos C., Soslow R.A. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol Jan 2010;, 23:781-789.